

8(*S*)-[(1*R*,2*S*,5*R*)-2-Isopropyl-5-methylcyclohexyloxy]-3,4-dihydro-2*H*-[1,4]dithiepine[2,3-*c*]furan-6(8*H*)-one

Alsu M. Khabibrakhmanova ¹, Enzhe S. Rabbanieva ¹, Darya P. Gerasimova ², Liliya Z. Latypova ¹ and Almira R. Kurbangalieva ^{1,*}

¹ Biofunctional Chemistry Laboratory, A. Butlerov Institute of Chemistry, Kazan Federal University, 18 Kremlyovskaya Street, 420008 Kazan, Russia

² Arbuzov Institute of Organic and Physical Chemistry, FRC Kazan Scientific Center of RAS, 8 Arbuzov Street, 420088 Kazan, Russia

* Correspondence: akurbang@kpfu.ru; Tel.: +7-843-233-74-62




Figure S1. ^1H (a) and $^{13}\text{C}\{^1\text{H}\}$ (b) NMR spectra of compound 2 (CDCl₃).




Figure S2. HSQC NMR spectrum of compound **2** (CDCl_3).




Figure S3. IR spectrum of compound 2.

Display Report

Acquisition Parameter

Source Type	ESI	Ion Polarity	Positive	Set Nebulizer	0.4 Bar
Focus	Not active			Set Dry Heater	180 °C
Scan Begin	50 m/z	Set Capillary	4500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z	Set End Plate Offset	-500 V	Set Divert Valve	Waste









Figure S4. Mass spectrum of compound 2.